Shandong Juntai Pharmaceutical Co., Ltd. is a high-tech, specialized and innovative enterprise integrating R&D, manufacturing and sales. We focus on providing high-quality pharmaceutical raw materials, advanced intermediates, peptide-related intermediates and cosmetic active ingredients for global customers. Our main product portfolio includes intermediates for Semaglutide, Tirzepatide, Retatrutide, Liraglutide, Insulin Degludec and other pharmaceutical projects, as well as peptide modifiers, protected amino acids, long-chain dicarboxylic acid derivatives, Pro-Xylane and Ectoine. We also provide custom synthesis, process development and scale-up manufacturing services. Juntai has established an approximately 1,500 m2 R&D center in Jinan High-tech Zone and has developed three core technical platforms: small-molecule chemistry, peptide modifiers and synthetic biology. The company operates three production bases located in Zaozhuang, Shanghe Provincial Chemical Park and Juancheng Chemical Park, enabling flexible support from laboratory development to commercial production. Following the principle of “Quality by Design,” we emphasize high purity, controlled impurities, batch-to-batch consistency and reliable delivery. Our quality control capabilities include HPLC, GC, LC-MS and other analytical testing methods. In 2020, Juntai expanded into the cosmetic ingredient sector and developed the KTcos? active ingredient portfolio. In 2023, KTcos? Pro-Xylane received the China Cosmetics Association Innovation Achievement Award and the First Prize of Science and Technology from the China General Chamber of Commerce. In March 2024, Juntai served as the chief editor of the group standard for Hydroxypropyl Tetrahydropyrantriol. With stable product quality and responsive technical support, Juntai has established cooperation with well-known companies including Gilead, Qilu Pharmaceutical, Chia Tai Tianqing Pharmaceutical, United Laboratories, Huadong Medicine and Huahai Pharmaceutica